Compile Data Set for Download or QSAR
Report error Found 55 Enz. Inhib. hit(s) with all data for entry = 50022555
TargetInsulin-like growth factor 1 receptor(Human)
OSI Pharmaceuticals, Inc.

Curated by ChEMBL
LigandPNGBDBM50219382(3-((1s,3s)-3-(4-methylpiperazin-1-yl)cyclobutyl)-1...)
Affinity DataIC50: 19nMAssay Description:Inhibition of human recombinant IGF-1 receptor expressed in mouse 3T3 cells treated for 15 mins by ELISA analysisMore data for this Ligand-Target Pair
In Depth
Date in BDB:
10/13/2025
Entry Details
PubMedPDB3D3D Structure (crystal)
TargetInsulin-like growth factor 1 receptor(Human)
OSI Pharmaceuticals, Inc.

Curated by ChEMBL
LigandPNGBDBM50315887((1s,3s)-3-(8-amino-1-(2-phenylquinolin-7-yl)imidaz...)
Affinity DataIC50: 24nMAssay Description:Inhibition of human recombinant IGF-1 receptor expressed in mouse 3T3 cells treated for 15 mins by ELISA analysisMore data for this Ligand-Target Pair
In Depth
Date in BDB:
10/13/2025
Entry Details
PubMed
TargetInsulin-like growth factor 1 receptor(Human)
OSI Pharmaceuticals, Inc.

Curated by ChEMBL
LigandPNGBDBM50315887((1s,3s)-3-(8-amino-1-(2-phenylquinolin-7-yl)imidaz...)
Affinity DataIC50: 24nMAssay Description:Inhibition of human recombinant IGF-1 receptor in presence of 100 uM ATP treated at 2 hrs followed by IGF1 ligand addition for 15 mins by ELISA analy...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/13/2025
Entry Details
PubMed
TargetInsulin-like growth factor 1 receptor(Human)
OSI Pharmaceuticals, Inc.

Curated by ChEMBL
LigandPNGBDBM50219382(3-((1s,3s)-3-(4-methylpiperazin-1-yl)cyclobutyl)-1...)
Affinity DataIC50: 24nMAssay Description:Inhibition of human recombinant IGF-1 receptor in presence of ATP by ELISA analysisMore data for this Ligand-Target Pair
In Depth
Date in BDB:
10/13/2025
Entry Details
PubMedPDB3D3D Structure (crystal)
TargetPlatelet-derived growth factor receptor alpha/beta(Mouse)
OSI Pharmaceuticals, Inc.

Curated by ChEMBL
LigandPNGBDBM50315887((1s,3s)-3-(8-amino-1-(2-phenylquinolin-7-yl)imidaz...)
Affinity DataIC50: 28nMAssay Description:Inhibition of ERK1/2 phosphorylation (unknown origin) expressed in mouse 3T3 cells treated at 2 hrs followed by IGF1 ligand addition for 15 mins by E...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/13/2025
Entry Details
PubMed
TargetInsulin-like growth factor 1 receptor(Human)
OSI Pharmaceuticals, Inc.

Curated by ChEMBL
LigandPNGBDBM50315887((1s,3s)-3-(8-amino-1-(2-phenylquinolin-7-yl)imidaz...)
Affinity DataIC50: 35nMAssay Description:Inhibition of human recombinant IGF-1 receptor expressed in mouse 3T3 cells treated at 2 hrs followed by IGF1 ligand addition for 15 mins by ELISA an...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/13/2025
Entry Details
PubMed
TargetInsulin-like growth factor 1 receptor(Human)
OSI Pharmaceuticals, Inc.

Curated by ChEMBL
LigandPNGBDBM50315887((1s,3s)-3-(8-amino-1-(2-phenylquinolin-7-yl)imidaz...)
Affinity DataIC50: 39nMAssay Description:Inhibition of human recombinant IGF-1 receptor expressed in mouse Hepa-1 cells treated for 15 mins by ELISA analysisMore data for this Ligand-Target Pair
In Depth
Date in BDB:
10/13/2025
Entry Details
PubMed
TargetInsulin-like growth factor 1 receptor(Human)
OSI Pharmaceuticals, Inc.

Curated by ChEMBL
LigandPNGBDBM50652892(CHEMBL5665369)
Affinity DataIC50: 42nMAssay Description:Inhibition of human recombinant IGF-1 receptor expressed in mouse 3T3 cells treated for 15 mins by ELISA analysisMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/13/2025
Entry Details
PubMed
TargetInsulin-like growth factor 1 receptor(Human)
OSI Pharmaceuticals, Inc.

Curated by ChEMBL
LigandPNGBDBM50339059(3-cyclobutyl-1-(2-phenylquinolin-7-yl)-imidazo[1,5...)
Affinity DataIC50: 59nMAssay Description:Inhibition of human recombinant IGF-1 receptor expressed in mouse 3T3 cells treated for 15 mins by ELISA analysisMore data for this Ligand-Target Pair
In Depth
Date in BDB:
10/13/2025
Entry Details
PubMed
TargetInsulin-like growth factor 1 receptor(Human)
OSI Pharmaceuticals, Inc.

Curated by ChEMBL
LigandPNGBDBM50339059(3-cyclobutyl-1-(2-phenylquinolin-7-yl)-imidazo[1,5...)
Affinity DataIC50: 64nMAssay Description:Inhibition of human recombinant IGF-1 receptor in presence of ATP by ELISA analysisMore data for this Ligand-Target Pair
In Depth
Date in BDB:
10/13/2025
Entry Details
PubMed
TargetInsulin-like growth factor 1 receptor(Human)
OSI Pharmaceuticals, Inc.

Curated by ChEMBL
LigandPNGBDBM50315887((1s,3s)-3-(8-amino-1-(2-phenylquinolin-7-yl)imidaz...)
Affinity DataIC50: 213nMAssay Description:Inhibition of human recombinant IGF-1 receptor in 90% human plasma measured by HPLC-MS/MS analysisMore data for this Ligand-Target Pair
In Depth
Date in BDB:
10/13/2025
Entry Details
PubMed
TargetInsulin receptor-related protein(Human)
OSI Pharmaceuticals, Inc.

Curated by ChEMBL
LigandPNGBDBM50315887((1s,3s)-3-(8-amino-1-(2-phenylquinolin-7-yl)imidaz...)
Affinity DataIC50: 750nMAssay Description:Inhibition of IRR (unknown origin) in presence of 100 uM ATP treated at 2 hrs followed by IGF1 ligand addition for 15 mins by ELISA analysisMore data for this Ligand-Target Pair
In Depth
Date in BDB:
10/13/2025
Entry Details
PubMed
TargetInsulin receptor(Human)
OSI Pharmaceuticals, Inc.

Curated by ChEMBL
LigandPNGBDBM50315887((1s,3s)-3-(8-amino-1-(2-phenylquinolin-7-yl)imidaz...)
Affinity DataIC50: 750nMAssay Description:Inhibition of IR (unknown origin) in presence of 100 uM ATP treated at 2 hrs followed by IGF1 ligand addition for 15 mins by ELISA analysisMore data for this Ligand-Target Pair
In Depth
Date in BDB:
10/13/2025
Entry Details
PubMed
TargetInsulin-like growth factor 1 receptor(Human)
OSI Pharmaceuticals, Inc.

Curated by ChEMBL
LigandPNGBDBM50199667(trans-4-(8-amino-1-(3-(benzyloxy)phenyl)imidazo[1,...)
Affinity DataIC50: 900nMAssay Description:Inhibition of human recombinant IGF-1 receptor expressed in mouse 3T3 cells treated for 15 mins by ELISA analysisMore data for this Ligand-Target Pair
In Depth
Date in BDB:
10/13/2025
Entry Details
PubMed
TargetInsulin-like growth factor 1 receptor(Human)
OSI Pharmaceuticals, Inc.

Curated by ChEMBL
LigandPNGBDBM50315887((1s,3s)-3-(8-amino-1-(2-phenylquinolin-7-yl)imidaz...)
Affinity DataIC50: 1.28E+3nMAssay Description:Inhibition of human recombinant IGF-1 receptor in 90% mouse plasma measured by HPLC-MS/MS analysisMore data for this Ligand-Target Pair
In Depth
Date in BDB:
10/13/2025
Entry Details
PubMed
TargetAurora kinase B(Human)
OSI Pharmaceuticals, Inc.

Curated by ChEMBL
LigandPNGBDBM50315887((1s,3s)-3-(8-amino-1-(2-phenylquinolin-7-yl)imidaz...)
Affinity DataIC50: 1.00E+4nMAssay Description:Inhibition of Aurora B (unknown origin) in presence of ATP Km treated at 2 hrs followed by IGF1 ligand addition for 15 mins by ELISA analysisMore data for this Ligand-Target Pair
In Depth
Date in BDB:
10/13/2025
Entry Details
PubMed
TargetAurora kinase A(Human)
OSI Pharmaceuticals, Inc.

Curated by ChEMBL
LigandPNGBDBM50315887((1s,3s)-3-(8-amino-1-(2-phenylquinolin-7-yl)imidaz...)
Affinity DataIC50: 1.00E+4nMAssay Description:Inhibition of Aurora A (unknown origin) in presence of ATP Km treated at 2 hrs followed by IGF1 ligand addition for 15 mins by ELISA analysisMore data for this Ligand-Target Pair
In Depth
Date in BDB:
10/13/2025
Entry Details
PubMed
TargetRAC-beta serine/threonine-protein kinase(Human)
OSI Pharmaceuticals, Inc.

Curated by ChEMBL
LigandPNGBDBM50315887((1s,3s)-3-(8-amino-1-(2-phenylquinolin-7-yl)imidaz...)
Affinity DataIC50: 1.00E+4nMAssay Description:Inhibition of AKT2 (unknown origin) in presence of ATP Km treated at 2 hrs followed by IGF1 ligand addition for 15 mins by ELISA analysisMore data for this Ligand-Target Pair
In Depth
Date in BDB:
10/13/2025
Entry Details
PubMed
TargetRAC-alpha serine/threonine-protein kinase(Human)
OSI Pharmaceuticals, Inc.

Curated by ChEMBL
LigandPNGBDBM50315887((1s,3s)-3-(8-amino-1-(2-phenylquinolin-7-yl)imidaz...)
Affinity DataIC50: 1.00E+4nMAssay Description:Inhibition of AKT1 (unknown origin) in presence of ATP Km treated at 2 hrs followed by IGF1 ligand addition for 15 mins by ELISA analysisMore data for this Ligand-Target Pair
In Depth
Date in BDB:
10/13/2025
Entry Details
PubMed
TargetMitogen-activated protein kinase 3(Human)
OSI Pharmaceuticals, Inc.

Curated by ChEMBL
LigandPNGBDBM50315887((1s,3s)-3-(8-amino-1-(2-phenylquinolin-7-yl)imidaz...)
Affinity DataIC50: 1.00E+4nMAssay Description:Inhibition of ERK1 (unknown origin) in presence of ATP Km treated at 2 hrs followed by IGF1 ligand addition for 15 mins by ELISA analysisMore data for this Ligand-Target Pair
In Depth
Date in BDB:
10/13/2025
Entry Details
PubMed
TargetMitogen-activated protein kinase 14(Human)
OSI Pharmaceuticals, Inc.

Curated by ChEMBL
LigandPNGBDBM50315887((1s,3s)-3-(8-amino-1-(2-phenylquinolin-7-yl)imidaz...)
Affinity DataIC50: 1.00E+4nMAssay Description:Inhibition of P38alpha (unknown origin) in presence of ATP Km treated at 2 hrs followed by IGF1 ligand addition for 15 mins by ELISA analysisMore data for this Ligand-Target Pair
In Depth
Date in BDB:
10/13/2025
Entry Details
PubMed
TargetSerine/threonine-protein kinase PLK1(Human)
OSI Pharmaceuticals, Inc.

Curated by ChEMBL
LigandPNGBDBM50315887((1s,3s)-3-(8-amino-1-(2-phenylquinolin-7-yl)imidaz...)
Affinity DataIC50: 1.00E+4nMAssay Description:Inhibition of PLK1 (unknown origin) in presence of ATP Km treated at 2 hrs followed by IGF1 ligand addition for 15 mins by ELISA analysisMore data for this Ligand-Target Pair
In Depth
Date in BDB:
10/13/2025
Entry Details
PubMed
LigandPNGBDBM50315887((1s,3s)-3-(8-amino-1-(2-phenylquinolin-7-yl)imidaz...)
Affinity DataIC50: 1.00E+4nMAssay Description:Inhibition of PDK1 (unknown origin) in presence of ATP Km treated at 2 hrs followed by IGF1 ligand addition for 15 mins by ELISA analysisMore data for this Ligand-Target Pair
In Depth
Date in BDB:
10/13/2025
Entry Details
PubMed
TargetCalcium/calmodulin-dependent protein kinase type 1D(Human)
OSI Pharmaceuticals, Inc.

Curated by ChEMBL
LigandPNGBDBM50315887((1s,3s)-3-(8-amino-1-(2-phenylquinolin-7-yl)imidaz...)
Affinity DataIC50: 1.00E+4nMAssay Description:Inhibition of CAMK1D (unknown origin) in presence of ATP Km treated at 2 hrs followed by IGF1 ligand addition for 15 mins by ELISA analysisMore data for this Ligand-Target Pair
In Depth
Date in BDB:
10/13/2025
Entry Details
PubMed
TargetGlycogen synthase kinase-3 alpha(Human)
OSI Pharmaceuticals, Inc.

Curated by ChEMBL
LigandPNGBDBM50315887((1s,3s)-3-(8-amino-1-(2-phenylquinolin-7-yl)imidaz...)
Affinity DataIC50: 1.00E+4nMAssay Description:Inhibition of GSK3alpha (unknown origin) in presence of ATP Km treated at 2 hrs followed by IGF1 ligand addition for 15 mins by ELISA analysisMore data for this Ligand-Target Pair
In Depth
Date in BDB:
10/13/2025
Entry Details
PubMed
TargetFocal adhesion kinase 1(Human)
OSI Pharmaceuticals, Inc.

Curated by ChEMBL
LigandPNGBDBM50315887((1s,3s)-3-(8-amino-1-(2-phenylquinolin-7-yl)imidaz...)
Affinity DataIC50: 1.00E+4nMAssay Description:Inhibition of FAK (unknown origin) in presence of ATP Km treated at 2 hrs followed by IGF1 ligand addition for 15 mins by ELISA analysisMore data for this Ligand-Target Pair
In Depth
Date in BDB:
10/13/2025
Entry Details
PubMed
TargetHigh affinity nerve growth factor receptor(Human)
OSI Pharmaceuticals, Inc.

Curated by ChEMBL
LigandPNGBDBM50315887((1s,3s)-3-(8-amino-1-(2-phenylquinolin-7-yl)imidaz...)
Affinity DataIC50: 1.00E+4nMAssay Description:Inhibition of TRKA (unknown origin) in presence of ATP Km treated at 2 hrs followed by IGF1 ligand addition for 15 mins by ELISA analysisMore data for this Ligand-Target Pair
In Depth
Date in BDB:
10/13/2025
Entry Details
PubMed
TargetHepatocyte growth factor receptor(Human)
OSI Pharmaceuticals, Inc.

Curated by ChEMBL
LigandPNGBDBM50315887((1s,3s)-3-(8-amino-1-(2-phenylquinolin-7-yl)imidaz...)
Affinity DataIC50: 1.00E+4nMAssay Description:Inhibition of MET (unknown origin) in presence of ATP Km treated at 2 hrs followed by IGF1 ligand addition for 15 mins by ELISA analysisMore data for this Ligand-Target Pair
In Depth
Date in BDB:
10/13/2025
Entry Details
PubMed
TargetTyrosine-protein kinase Lyn(Human)
OSI Pharmaceuticals, Inc.

Curated by ChEMBL
LigandPNGBDBM50315887((1s,3s)-3-(8-amino-1-(2-phenylquinolin-7-yl)imidaz...)
Affinity DataIC50: 1.00E+4nMAssay Description:Inhibition of LYN B (unknown origin) in presence of ATP Km treated at 2 hrs followed by IGF1 ligand addition for 15 mins by ELISA analysisMore data for this Ligand-Target Pair
In Depth
Date in BDB:
10/13/2025
Entry Details
PubMed
TargetCyclin-dependent kinase 1(Human)
OSI Pharmaceuticals, Inc.

Curated by ChEMBL
LigandPNGBDBM50315887((1s,3s)-3-(8-amino-1-(2-phenylquinolin-7-yl)imidaz...)
Affinity DataIC50: 1.00E+4nMAssay Description:Inhibition of CDK1 (unknown origin) in presence of ATP Km treated at 2 hrs followed by IGF1 ligand addition for 15 mins by ELISA analysisMore data for this Ligand-Target Pair
In Depth
Date in BDB:
10/13/2025
Entry Details
PubMed
TargetSerine/threonine-protein kinase pim-1(Human)
OSI Pharmaceuticals, Inc.

Curated by ChEMBL
LigandPNGBDBM50315887((1s,3s)-3-(8-amino-1-(2-phenylquinolin-7-yl)imidaz...)
Affinity DataIC50: 1.00E+4nMAssay Description:Inhibition of PIM1 (unknown origin) in presence of ATP Km treated at 2 hrs followed by IGF1 ligand addition for 15 mins by ELISA analysisMore data for this Ligand-Target Pair
In Depth
Date in BDB:
10/13/2025
Entry Details
PubMed
TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
OSI Pharmaceuticals, Inc.

Curated by ChEMBL
LigandPNGBDBM50315887((1s,3s)-3-(8-amino-1-(2-phenylquinolin-7-yl)imidaz...)
Affinity DataIC50: 1.00E+4nMAssay Description:Inhibition of RET (unknown origin) in presence of ATP Km treated at 2 hrs followed by IGF1 ligand addition for 15 mins by ELISA analysisMore data for this Ligand-Target Pair
In Depth
Date in BDB:
10/13/2025
Entry Details
PubMed
TargetProtein-tyrosine kinase 6(Human)
OSI Pharmaceuticals, Inc.

Curated by ChEMBL
LigandPNGBDBM50315887((1s,3s)-3-(8-amino-1-(2-phenylquinolin-7-yl)imidaz...)
Affinity DataIC50: 1.00E+4nMAssay Description:Inhibition of BRK (unknown origin) in presence of ATP Km treated at 2 hrs followed by IGF1 ligand addition for 15 mins by ELISA analysisMore data for this Ligand-Target Pair
In Depth
Date in BDB:
10/13/2025
Entry Details
PubMed
TargetProto-oncogene tyrosine-protein kinase Src(Human)
OSI Pharmaceuticals, Inc.

Curated by ChEMBL
LigandPNGBDBM50315887((1s,3s)-3-(8-amino-1-(2-phenylquinolin-7-yl)imidaz...)
Affinity DataIC50: 1.00E+4nMAssay Description:Inhibition of SRC (unknown origin) in presence of ATP Km treated at 2 hrs followed by IGF1 ligand addition for 15 mins by ELISA analysisMore data for this Ligand-Target Pair
In Depth
Date in BDB:
10/13/2025
Entry Details
PubMed
TargetProto-oncogene tyrosine-protein kinase ROS(Human)
OSI Pharmaceuticals, Inc.

Curated by ChEMBL
LigandPNGBDBM50315887((1s,3s)-3-(8-amino-1-(2-phenylquinolin-7-yl)imidaz...)
Affinity DataIC50: 1.00E+4nMAssay Description:Inhibition of ROS1 (unknown origin) in presence of ATP Km treated at 2 hrs followed by IGF1 ligand addition for 15 mins by ELISA analysisMore data for this Ligand-Target Pair
In Depth
Date in BDB:
10/13/2025
Entry Details
PubMed
TargetMacrophage-stimulating protein receptor(Human)
OSI Pharmaceuticals, Inc.

Curated by ChEMBL
LigandPNGBDBM50315887((1s,3s)-3-(8-amino-1-(2-phenylquinolin-7-yl)imidaz...)
Affinity DataIC50: 1.00E+4nMAssay Description:Inhibition of RON (unknown origin) in presence of ATP Km treated at 2 hrs followed by IGF1 ligand addition for 15 mins by ELISA analysisMore data for this Ligand-Target Pair
In Depth
Date in BDB:
10/13/2025
Entry Details
PubMed
TargetDual specificity tyrosine-phosphorylation-regulated kinase 3(Human)
OSI Pharmaceuticals, Inc.

Curated by ChEMBL
LigandPNGBDBM50315887((1s,3s)-3-(8-amino-1-(2-phenylquinolin-7-yl)imidaz...)
Affinity DataIC50: 1.00E+4nMAssay Description:Inhibition of DYRK3 (unknown origin) in presence of ATP Km treated at 2 hrs followed by IGF1 ligand addition for 15 mins by ELISA analysisMore data for this Ligand-Target Pair
In Depth
Date in BDB:
10/13/2025
Entry Details
PubMed
TargetSerine/threonine-protein kinase TAO2(Human)
OSI Pharmaceuticals, Inc.

Curated by ChEMBL
LigandPNGBDBM50315887((1s,3s)-3-(8-amino-1-(2-phenylquinolin-7-yl)imidaz...)
Affinity DataIC50: 1.00E+4nMAssay Description:Inhibition of TAOK2 (unknown origin) in presence of ATP Km treated at 2 hrs followed by IGF1 ligand addition for 15 mins by ELISA analysisMore data for this Ligand-Target Pair
In Depth
Date in BDB:
10/13/2025
Entry Details
PubMed
TargetSerine/threonine-protein kinase PAK 3(Human)
OSI Pharmaceuticals, Inc.

Curated by ChEMBL
LigandPNGBDBM50315887((1s,3s)-3-(8-amino-1-(2-phenylquinolin-7-yl)imidaz...)
Affinity DataIC50: 1.00E+4nMAssay Description:Inhibition of PAK3 (unknown origin) in presence of ATP Km treated at 2 hrs followed by IGF1 ligand addition for 15 mins by ELISA analysisMore data for this Ligand-Target Pair
In Depth
Date in BDB:
10/13/2025
Entry Details
PubMed
TargetDual specificity mitogen-activated protein kinase kinase 1(Human)
OSI Pharmaceuticals, Inc.

Curated by ChEMBL
LigandPNGBDBM50315887((1s,3s)-3-(8-amino-1-(2-phenylquinolin-7-yl)imidaz...)
Affinity DataIC50: 1.00E+4nMAssay Description:Inhibition of MEK1 (unknown origin) in presence of ATP Km treated at 2 hrs followed by IGF1 ligand addition for 15 mins by ELISA analysisMore data for this Ligand-Target Pair
In Depth
Date in BDB:
10/13/2025
Entry Details
PubMed
TargetAngiopoietin-1 receptor(Human)
OSI Pharmaceuticals, Inc.

Curated by ChEMBL
LigandPNGBDBM50315887((1s,3s)-3-(8-amino-1-(2-phenylquinolin-7-yl)imidaz...)
Affinity DataIC50: 1.00E+4nMAssay Description:Inhibition of TEK (unknown origin) in presence of ATP Km treated at 2 hrs followed by IGF1 ligand addition for 15 mins by ELISA analysisMore data for this Ligand-Target Pair
In Depth
Date in BDB:
10/13/2025
Entry Details
PubMed
TargetTyrosine-protein kinase BTK(Human)
OSI Pharmaceuticals, Inc.

Curated by ChEMBL
LigandPNGBDBM50315887((1s,3s)-3-(8-amino-1-(2-phenylquinolin-7-yl)imidaz...)
Affinity DataIC50: 1.00E+4nMAssay Description:Inhibition of BTK (unknown origin) in presence of ATP Km treated at 2 hrs followed by IGF1 ligand addition for 15 mins by ELISA analysisMore data for this Ligand-Target Pair
In Depth
Date in BDB:
10/13/2025
Entry Details
PubMed
TargetALK tyrosine kinase receptor(Human)
OSI Pharmaceuticals, Inc.

Curated by ChEMBL
LigandPNGBDBM50315887((1s,3s)-3-(8-amino-1-(2-phenylquinolin-7-yl)imidaz...)
Affinity DataIC50: 1.00E+4nMAssay Description:Inhibition of ALK (unknown origin) in presence of ATP Km treated at 2 hrs followed by IGF1 ligand addition for 15 mins by ELISA analysisMore data for this Ligand-Target Pair
In Depth
Date in BDB:
10/13/2025
Entry Details
PubMed
TargetTyrosine-protein kinase Fes/Fps(Human)
OSI Pharmaceuticals, Inc.

Curated by ChEMBL
LigandPNGBDBM50315887((1s,3s)-3-(8-amino-1-(2-phenylquinolin-7-yl)imidaz...)
Affinity DataIC50: 1.00E+4nMAssay Description:Inhibition of FES (unknown origin) in presence of ATP Km treated at 2 hrs followed by IGF1 ligand addition for 15 mins by ELISA analysisMore data for this Ligand-Target Pair
In Depth
Date in BDB:
10/13/2025
Entry Details
PubMed
TargetEphrin type-B receptor 1(Human)
OSI Pharmaceuticals, Inc.

Curated by ChEMBL
LigandPNGBDBM50315887((1s,3s)-3-(8-amino-1-(2-phenylquinolin-7-yl)imidaz...)
Affinity DataIC50: 1.00E+4nMAssay Description:Inhibition of EPHB1 (unknown origin) in presence of ATP Km treated at 2 hrs followed by IGF1 ligand addition for 15 mins by ELISA analysisMore data for this Ligand-Target Pair
In Depth
Date in BDB:
10/13/2025
Entry Details
PubMed
TargetEphrin type-A receptor 1(Human)
OSI Pharmaceuticals, Inc.

Curated by ChEMBL
LigandPNGBDBM50315887((1s,3s)-3-(8-amino-1-(2-phenylquinolin-7-yl)imidaz...)
Affinity DataIC50: 1.00E+4nMAssay Description:Inhibition of EPHA1 (unknown origin) in presence of ATP Km treated at 2 hrs followed by IGF1 ligand addition for 15 mins by ELISA analysisMore data for this Ligand-Target Pair
In Depth
Date in BDB:
10/13/2025
Entry Details
PubMed
TargetEpidermal growth factor receptor(Human)
OSI Pharmaceuticals, Inc.

Curated by ChEMBL
LigandPNGBDBM50315887((1s,3s)-3-(8-amino-1-(2-phenylquinolin-7-yl)imidaz...)
Affinity DataIC50: 1.00E+4nMAssay Description:Inhibition of EGFR (unknown origin) in presence of ATP Km treated at 2 hrs followed by IGF1 ligand addition for 15 mins by ELISA analysisMore data for this Ligand-Target Pair
In Depth
Date in BDB:
10/13/2025
Entry Details
PubMed
TargetInterleukin-1 receptor-associated kinase 4(Human)
OSI Pharmaceuticals, Inc.

Curated by ChEMBL
LigandPNGBDBM50315887((1s,3s)-3-(8-amino-1-(2-phenylquinolin-7-yl)imidaz...)
Affinity DataIC50: 1.00E+4nMAssay Description:Inhibition of IRAK4 (unknown origin) in presence of ATP Km treated at 2 hrs followed by IGF1 ligand addition for 15 mins by ELISA analysisMore data for this Ligand-Target Pair
In Depth
Date in BDB:
10/13/2025
Entry Details
PubMed
TargetRho-associated protein kinase 1(Human)
OSI Pharmaceuticals, Inc.

Curated by ChEMBL
LigandPNGBDBM50315887((1s,3s)-3-(8-amino-1-(2-phenylquinolin-7-yl)imidaz...)
Affinity DataIC50: 1.00E+4nMAssay Description:Inhibition of ROCK1 (unknown origin) in presence of ATP Km treated at 2 hrs followed by IGF1 ligand addition for 15 mins by ELISA analysisMore data for this Ligand-Target Pair
In Depth
Date in BDB:
10/13/2025
Entry Details
PubMed
TargetProtein kinase C alpha type(Human)
OSI Pharmaceuticals, Inc.

Curated by ChEMBL
LigandPNGBDBM50315887((1s,3s)-3-(8-amino-1-(2-phenylquinolin-7-yl)imidaz...)
Affinity DataIC50: 1.00E+4nMAssay Description:Inhibition of PKC-alpha (unknown origin) in presence of ATP Km treated at 2 hrs followed by IGF1 ligand addition for 15 mins by ELISA analysisMore data for this Ligand-Target Pair
In Depth
Date in BDB:
10/13/2025
Entry Details
PubMed
Displayed 1 to 50 (of 55 total ) | Next | Last >>
Jump to: